ONCT - Oncternal Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-26.27M

Cash

45.5M

Avg Qtr Burn

-10.3M

Short % of Float

0.52%

Insider Ownership

8.62%

Institutional Own.

19.57%

Qtr Updated

06/30/23

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ONCT-534 Details Cancer, Castration-resistant prostate cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ONCT-808 (CAR-T) Details Hematologic malignancies, Cancer, B-cell lymphoma	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zilovertamab (Cirmtuzumab) (ROR1) + Ibrutinib Details Blood cancer, Chronic lymphocytic leukemia, Cancer, Mantle cell lymphoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zilovertamab (Cirmtuzumab) (ROR1) + Paclitaxel Details Cancer, Metastatic breast cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zilovertamab (Cirmtuzumab) (ROR1) + Ibrutinib Details Blood cancer, Cancer, Mantle cell lymphoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ONCT-216 (TK216) (EWS-FLI1 inhibitor) Details Relapsed/refractory Ewing sarcoma, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.